Facial Erythema and Telangiectasia
Conditions
Interventions
Experimental group:Topical formulation containing hyaluronic acid-modified tranexamic acid metal-organic frameworks, and oral Compound Glycyrrhizin Tablets
Control group:Topical formulation without hyaluronic acid-modified tranexamic acid metal-organic frameworks, and oral Compound Glycyrrhizin Tablets
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Voluntarily participated in this trial, signed the informed consent form, and agreed to use the product and undergo testing; 2) Aged between 20 and 60 years old, with no restrictions on gender; 3) Presenting clinical manifestations of facial erythema and telangiectasia that conform to the diagnostic criteria in Dermatology. If a primary disease is present, it must meet the diagnostic criteria for erythematotelangiectatic rosacea (ETR) and sensitive skin, utilizing the Guidelines for Diagnosis and Treatment of Rosacea in China (2021 Edition) and the Guidelines for Clinical Diagnosis and Treatment of Sensitive Skin in China (2024 Edition).
Exclusion criteria
Exclusion criteria: 1) Failed to sign/complete the informed consent form; 2) Pregnant, potentially pregnant, or lactating women; 3) Used oral or topical tranexamic acid within the past month; 4) Currently taking oral contraceptives or receiving hormone replacement therapy (HRT); 4) Known allergy to any ingredient of the product, or individuals with a severe allergic constitution; 5) Suffering from severe or progressive diseases where, in the judgment of the investigator, participation in this clinical trial would pose an inappropriate risk to the subject (e.g., cancer or symptoms of cancer, immunocompromised status, uncontrolled diabetes, epilepsy, or severe cardiac, hepatic, or renal insufficiency); 6) Presenting with facial erythema caused by other erythematous, immunological, or infectious skin diseases; 7) Possessing contraindications to the use of Compound Glycyrrhizin Tablets, including myopathy, aldosteronism, hypokalemia, and liver cirrhosis; 8) Other conditions that, in the opinion of the investigator, make the subject unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinician’s erythema assessment;Elangiectasia grading score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of product satisfaction;Investigator’s global assessment;Patient’s self-assessment;Patient Global Assessment; | — |
Countries
China
Contacts
Public ContactLi Li
West China Hospital, Sichuan University
Outcome results
None listed